This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
This week in the Conference Coverage section of the CLL Society website, we have posted an interview from ASH 2015 where I spoke with Dr. Nitin Jain about the RESONATE-2 trial that compared ibrutinib to chlorambucil in the frontline setting for patients over 65. You can see that interview here. We’ve also posted an audio interview with CLL expert, Bruce Cheson that was recorded at the North American Educational Forum on Lymphoma, a meeting of the Lymphoma Research Foundation that took place in October. Dr. Cheson talks about personalized therapy in CLL. You can listen to our interview here.
If you enjoy Conference Coverage, we also provide timely and informative articles from recent conferences within our quarterly newsletters, The CLL Tribune. In our first issue, I interviewed Dr. Jennifer Brown from the 2015 iwCLL meeting about what idelalisib is, how it works and what the findings have been. You can access that interview here.
In our second issue published a month ago, we published an interview from ASH 2015 with Dr. John Byrd about ACP-196. You can access that article here.
One goal for 2016 in addressing the unmet needs of those affected by CLL is to answer questions from our readers. You can submit your own questions to our medical advisory board here. Select questions will be answered in the next issue of The CLL Tribune expected at the end of March. You can read the Ask The Doctor section to read Dr. Furman’s answers to questions submitted to our last issue.
We are all in this together.
Volunteer Medical Director of the CLL Society